ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "renal disease and systemic lupus erythematosus (SLE)"

  • Abstract Number: 722 • ACR/ARHP Annual Meeting 2018

    Increased Blood Pressure Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus: Association with Inflammation, Comorbidities and Increased Mortality

    Tyler Reese1, Alyson Dickson1, Jacquelyn E. Neal2, Jocelyn S. Gandelman3, Omair A. Khan2, April Barnado4, William Dupont2, C. Michael Stein1 and Cecilia P. Chung1, 1Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 2Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 3Vanderbilt University School of Medicine, Nashville, TN, 4Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased mortality compared to the general population. As outcomes related to disease control have improved, this mortality…
  • Abstract Number: 735 • ACR/ARHP Annual Meeting 2018

    Serum Albumin at One Year Predicts Long-Term Renal Outcome

    Vinicius Domingues1, Daniel Goldman2, Laurence S Magder3 and Michelle Petri2, 1Medicine, New York University School of Medicine, New York, NY, 2Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, 3Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose:   Lupus nephritis remains a major cause of morbidity/mortality in SLE.  Our cohort has shown that 20% of SLE patients with lupus nephritis onset…
  • Abstract Number: 739 • ACR/ARHP Annual Meeting 2018

    Urine and Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Differentially Correlates with Renal and Non-Renal Systemic Lupus Erythematosus (SLE): A Prospective, Case-Control Study

    Yair Molad1,2, Mohammad Egbaria3, Ariela Dortort-Lazar4,5, Elisheva Pokroy-Shapira3,5, Shirly Oren4, Yonatan Edel3,5 and Vitaly Kliminski5,6, 1Rheumatology Unit, Rabin Medical Center - Beilinson Campus, Petah-Tiqva, Israel, 2Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel, 3Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, 4Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, 5Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 6Laboratory of Inflammation Research, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel

    Background/Purpose: Elevated levels of sTREM-1 have been previously found in patients with SLE. A prospective, case-control, longitudinal study aimed to assess the value of urinary…
  • Abstract Number: 763 • ACR/ARHP Annual Meeting 2018

    Comparison of Clinical Characteristics and Outcome between Isolated and Classic Lupus Nephritis

    Kubra Bugdayli1, Cynthia S. Crowson2, Ladan Zand3, Mariam P. Alexander4, Lynn D. Cornell4 and Vaidehi R. Chowdhary5, 1Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Nephrology and Hypertension, Mayo Clinic, Rochester, MN, 4Anatomic Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN, 5Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN

    Comparison of clinical characteristics and outcome between isolated and classic lupus nephritisBackground/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE). Rarely,…
  • Abstract Number: 765 • ACR/ARHP Annual Meeting 2018

    Predictors of End-Stage Renal Disease in Lupus Nephritis

    Mery Deeb1, Konstantinos Tselios2, Dafna D Gladman2, Jiandong Su2 and Murray Urowitz3, 1Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toront, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: End-stage renal disease (ESRD) is the most important complication of lupus nephritis (LN) and greatly affects mortality. Its incidence has been estimated at 11%…
  • Abstract Number: 665 • ACR/ARHP Annual Meeting 2017

    Low Vitamin D Is Associated with End Stage Renal Disease in Systemic Lupus Erythematosus

    Michelle Petri1, Wei Fu2 and Daniel Goldman2, 1Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, 2Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Vitamin D insufficiency/deficiency is common in SLE. Replacement therapy may help renal disease activity. We asked whether low vitamin D predicted later organ damage.…
  • Abstract Number: 2621 • ACR/ARHP Annual Meeting 2017

    Minimal Renal Affection in Patients with Systemic LUPUS Erythematosus: Characteristics and Evolution

    TC Salman-Monte1, Eva Rodriguez2, José Luis Arevalos3, María José Soler3, Clara Barrios3, Jordi Carbonell4 and Julio Pascual3, 1Rheumatology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, 2Nephrology, Hospital del Mar/ Parc de Salut Mar, Barcelona, Spain, 3Nephrology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, 4Rheumatology Unit, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain

    Background/Purpose: Lupus nephritis (LN) is the most common organ involvement in Systemic Lupus Erythematosus (SLE). Indications of renal biopsy (RB) are deterioration of renal function…
  • Abstract Number: 2622 • ACR/ARHP Annual Meeting 2017

    The Benefit of Vitamin D on SLE Disease Activity Is Largely Explained By Renal Activity

    Michelle Petri1, Daniel Goldman2 and Laurence S Magder3, 1Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, 2Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Low vitamin D is commonly found in SLE. In previous studies, supplementation of vitamin D resulted in improvement in the Physician Global Assessment and…
  • Abstract Number: 1181 • ACR/ARHP Annual Meeting 2016

    Risk Factors for Incident Fractures in Patients with Systemic Lupus Erythematosus on Dialysis

    Brian Le1,2, Jennifer Waller3, Reshmitha Radhakrishnan4, Sun Jung Oh4, Monique Bethel2,5, Christopher Rice4 and Laura Carbone2,6, 1Department of Internal Medicine, Augusta University, Augusta, GA, 2Specialty Care, Charlie Norwood VA Medical Center, Augusta, GA, 3Biostatistics, Augusta University, Augusta, GA, 4School of Medicine, Augusta University, Augusta, GA, 51120 15th Street, BI 5070, Augusta University, Augusta, GA, 6Rheumatology, Augusta University, Augusta, GA

    Background/Purpose:  Osteoporosis and osteoporotic fractures are significant comorbidities in patients with systemic lupus erythematosus (SLE). Hip fractures are being increasingly recognized as a complication of…
  • Abstract Number: 2827 • ACR/ARHP Annual Meeting 2016

    Prognostic Significance of Repeat Biopsy in Lupus Nephritis: Histopathologic Worsening Is an Independent Risk Factor for End Stage Renal Disease and Death

    Cristina Arriens1, Sixia Chen2, David Karp3, Ramesh Saxena4, Kamalanathan Sambandam4, Eliza Chakravarty1, Judith A. James5 and Joan T. Merrill6, 1Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, 4Internal Medicine/Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, 5Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose:  Approximately half of SLE patients develop lupus nephritis (LN), a major cause of morbidity and early mortality. It is known that prolonged renal inflammation…
  • Abstract Number: 2868 • ACR/ARHP Annual Meeting 2016

    NK Cell Characterization in Patients with Systemic Lupus Erythematosus: Increased Frequency of Ki67+ NK Cells Associated with Disease Activity and Type I Interferon Signature

    Kelly Hudspeth1, Shu Wang2, Jingya Wang2, Saifur Rahman2, Michael Smith2, Kerry Casey2, Geoffrey Stephens3, Miguel Sanjuan2, Autoimmunity Molecular Medicine group2, Zerai G. Manna4, Sarfaraz Hasni4, Rachel Ettinger5 and Richard Siegel6, 1Immunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Respiratory, Inflammation, and Autoimmunity Group, MedImmune LLC, Gaithersburg, MD, 3Respiratory, Inflammatory, and Autoimmune Diseases Research, Medimmune, LLC, Gaithersburg, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5Respiratory, Inflammation and Autoimmunity (RIA), MedImmune, LLC, Gaithersburg, MD, 6Immunoregulation Section, Autoimmunity Branch and Office of the Clinical Director National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder whose pathology appears to involve many immune cell types. While it is clear that autoantibody…
  • Abstract Number: 1658 • ACR/ARHP Annual Meeting 2014

    Renal Thrombotic Microangiopathy in Systemic Lupus Erythematosus: Novel Risk Factors and Clinical Outcomes

    Ana Barrera-Vargas1, Rodrigo Rosado-Canto2, Javier Merayo-Chalico3, Jorge Alcocer-Varela1 and Diana Gómez-Martín1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, 3Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: Thrombotic microangiopathy (TMA) is characterized by microvascular occlusion, systemic or intrarenal platelet aggregation and mechanical injury to erythrocytes.  It is a pathological endpoint that…
  • Abstract Number: 594 • ACR/ARHP Annual Meeting 2013

    Renal Biopsy Findings In Lupus Patient With Insignificant Proteinuria : Relation To Disease Activity and Clinical Manifestations

    Abdel Azeim M. Al-Hefny1, Samah El-bakry2, Sameh A. Mobasher3, Ola H. Nada4 and Nouran Abaza5, 1Department of Internal Medicine and Rheumatology, Professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, Cairo, Egypt, 2Department of Internal Medicine and Rheumatology, Assistant professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 3Department of Internal Medicine and Rheumatology, Lecturer of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 4Department of Pathology, Faculty of Medicine, Ain Shams University, Lecturer of Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 5Physical medicine, Rheumatology and Rehabilitation, Lecturer of Physical medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Background/Purpose: Lupus nephritis (LN) remains one of the most serious manifestations of systemic lupus erythematosus (SLE) and is associated with significant morbidity and mortality. Early…
  • Abstract Number: 618 • ACR/ARHP Annual Meeting 2013

    Active Renal Disease Is Associated With The Presence Of The Metabolic Syndrome (MetS) In Peruvian Patients With Systemic Lupus Erythematosus (SLE)

    Manuel F. Ugarte-Gil1,2, Rocio V. Gamboa-Cardenas3, Mariela Medina-Chinchon1, Francisco Zevallos-Miranda1, Karim E. Diaz-Deza3, J. Mariano Cucho-Venegas1, Zoila Rodriguez-Bellido1,4, Jose L. Alfaro-Lozano1, Risto A. Perich-Campos1,4, Erika Noriega3, Hugo Torrealva1 and Cesar A. Pastor-Asurza1,4, 1Rheumatology, Hospital Guillermo Almenara, EsSalud, Lima, Peru, 2Universidad Cientifica del Sur, Lima, Peru, 3Rheumatology, Hospital Almenara, Lima, Peru, 4Universidad Nacional Mayor de San Marcos, Lima, Peru

    Background/Purpose: The MetS prevalence is increased in SLE patients, in particular in those of Hispanic origin and it is associated with a higher risk for…
  • Abstract Number: 2265 • ACR/ARHP Annual Meeting 2012

    Clinical Manifestations of Systemic Lupus Erythematosus Vary Based On Age of Disease Onset

    Flora Simmons1, Natasha M. Ruth2, Gary S. Gilkeson3 and Diane L. Kamen4, 1Rheumatology, Medical University of South Carolina, Charleston, SC, 2Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, 3Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 4Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC

    Background/Purpose:  Systemic lupus erythematosus (SLE) is an autoimmune disease which disproportionately affects women of child-bearing age.  However, onset during childhood and late adult onset can…
  • 1
  • 2
  • Next Page

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology